Abstract
<p>Supplemental Figure 1. Flowchart of the "Skin Cancer Prevention Study" randomized clinical trial (RCT) design from which the study group was derived. Supplemental Figure 2. Robustness of human polyomavirus (PyV) seroprevalence estimates among 229 controls from the Skin Cancer Prevention Study. Supplemental Figure 3. Robustness of odds ratio (OR) estimates obtained from conditional logistic regression analysis for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus (PyV) type among 306 study participants from the Skin Cancer Prevention Study. Supplemental Figure 4. Robustness of odds ratio (OR) estimates obtained from unconditional logistic regression analysis for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus (PyV) type among 342 study participants from the Skin Cancer Prevention Study, with adjustment for continuous age, gender, and study center. Supplemental Figure 5. Plot of conditional (left) and unconditional (right) odds ratios (95% confidence intervals as whiskers) for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus type among study participants from the Skin Cancer Prevention Study. Supplemental Figure 6. Plot of conditional (left) and unconditional (right) odds ratios (95% confidence intervals as whiskers) for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus type among study participants from the Skin Cancer Prevention Study. Supplemental Table 1. Distribution of BK and JC human polyomavirus (PyV) seropositivity by selected baseline characteristics among 229 controls from the Skin Cancer Prevention Study. Supplemental Table 2. Unconditional odds ratios (95% confidence intervals) for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus (PyV) type and quartiles of PyV seroreactivity at baseline among 342 study participants from the Skin Cancer Prevention Study.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
